Kyverna Therapeutics, Inc. KYTX Фондовый прогноз
ИИ-прогноз цены и анализ для Kyverna Therapeutics, Inc. · Обновленный Апр 02, 2026
ИИ-прогноз на 90 дней
СИЛЬНАЯ ПОКУПКА
7 дней
30 дней
90 дней
Уверенность AI: 55% Корреляция Спирмена
Апрель 02, 2026
Посмотреть точную целевую цену KYTX
Создайте бесплатный аккаунт, чтобы разблокировать ИИ-прогнозы для более 4 000 акций
Зарегистрируйтесь бесплатно через Google✓ Бесплатный аккаунт · ✓ Пробный период 30 дней · ✓ Отмена в любое время
График цен
Загрузка графика...
Ключевые показатели
Рыночная капитализация
$530M
Коэффициент P/B
2,28x
EPS
$-3,68
О сайте Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX) работает в секторе Life Sciences, в частности в отрасли Biological Products, (No Diagnostic Substances). .
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by …
Последние новости
- Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
- Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
- Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
- Зарегистрируйтесь бесплатно, чтобы прочитать все 12 статей →
Biological Products, (No Diagnostic Substances) Сопоставимые компании
| Компания | Тикер | ИИ-сигнал | Рыночная капитализация | P/E |
|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. | ABOS | ██% | $188M | -1,9x |
| Abpro Holdings, Inc. | ABP | ██% | $310K | -x |
| Abpro Holdings, Inc. | ABPO | ██% | $460K | -x |
| Arcellx, Inc. | ACLX | ██% | $6.65B | -74,1x |
| Alpha Cognition Inc. | ACOG | ██% | $134M | -x |
| Adaptimmune Therapeutics Plc | ADAP | ██% | $77M | -13,2x |
| Adma Biologics, Inc. | ADMA | ██% | $2.17B | 14,8x |
| Adaptive Biotechnologies Corp | ADPT | ██% | $2.25B | -4,6x |
| Adverum Biotechnologies, Inc. | ADVM | ██% | $95M | -1,8x |
| Agenus Inc | AGEN | ██% | $120M | 1047,3x |
| Agentix Corp. | AGTX | ██% | $2M | -x |
| Aim Immunotech Inc. | AIM | ██% | $2M | -0,5x |
| Aim Immunotech Inc. | AIMI | ██% | $1M | -x |
| Alector, Inc. | ALEC | ██% | $251M | -1,2x |
| Aligos Therapeutics, Inc. | ALGS | ██% | $49M | -19,2x |
| Allogene Therapeutics, Inc. | ALLO | ██% | $593M | -1,4x |
| Alvotech | ALVO | ██% | $1.13B | -x |
| Amgen Inc | AMGN | ██% | $190.18B | 24,7x |
| Apogee Therapeutics, Inc. | APGE | ██% | $5.77B | -20,5x |
| Aptose Biosciences Inc. | APTOF | ██% | $4M | -x |
| Argenx Se | ARGX | ██% | $46.03B | -x |
| Armata Pharmaceuticals, Inc. | ARMP | ██% | $378M | -1,0x |
| Artiva Biotherapeutics, Inc. | ARTV | ██% | $165M | -x |
| Leonabio, Inc. | ATHA | ██% | $23M | -0,2x |
| Atara Biotherapeutics, Inc. | ATRA | ██% | $42M | 1,3x |
| Atyr Pharma Inc | ATYR | ██% | $84M | -3,6x |
| Aura Biosciences, Inc. | AURA | ██% | $416M | -4,9x |
| Autolus Therapeutics Plc | AUTL | ██% | $374M | -x |
| Anavex Life Sciences … | AVXL | ██% | $279M | -17,3x |
| Bioatla, Inc. | BCAB | ██% | $11M | -1,1x |
| Biocardia, Inc. | BCDA | ██% | $12M | -0,6x |
| Brainstorm Cell Therapeutics … | BCLI | ██% | $10M | -4,9x |
| Biocryst Pharmaceuticals Inc | BCRX | ██% | $2.35B | 8,9x |
| Black Diamond Therapeutics, … | BDTX | ██% | $133M | 6,0x |
| Beam Therapeutics Inc. | BEAM | ██% | $2.46B | -12,6x |
| Biogen Inc. | BIIB | ██% | $26.98B | 20,9x |
| Biontech Se | BNTX | ██% | $22.47B | -x |
| Cabaletta Bio, Inc. | CABA | ██% | $269M | -1,6x |
| Candel Therapeutics, Inc. | CADL | ██% | $365M | -4,6x |
| C4 Therapeutics, Inc. | CCCC | ██% | $262M | -2,6x |
| Cidara Therapeutics, Inc. | CDTX | ██% | $6.49B | -1,0x |
| Creative Medical Technology … | CELZ | ██% | $7M | -3,4x |
| Cero Therapeutics Holdings, … | CERO | ██% | $650K | -x |
| Cullinan Therapeutics, Inc. | CGEM | ██% | $840M | -4,1x |
| Compugen Ltd | CGEN | ██% | $211M | 3,0x |
| Cg Oncology, Inc. | CGON | ██% | $5.39B | -x |
| Cognition Therapeutics Inc | CGTX | ██% | $76M | -0,5x |
| Coherus Oncology, Inc. | CHRS | ██% | $256M | 1,5x |
| Calidi Biotherapeutics, Inc. | CLDI | ██% | $2M | -0,9x |
| Cellectis S.A. | CLLS | ██% | $344M | -x |
| Compass Therapeutics, Inc. | CMPX | ██% | $968M | -4,8x |
| Mosaic Immunoengineering Inc. | CPMV | ██% | $5M | -x |
| Caribou Biosciences, Inc. | CRBU | ██% | $142M | -1,5x |
| Cardiff Oncology, Inc. | CRDF | ██% | $110M | -4,0x |
| Cardiol Therapeutics Inc. | CRDL | ██% | $156M | -x |
| Curis Inc | CRIS | ██% | $22M | -0,3x |
| Crispr Therapeutics Ag | CRSP | ██% | $4.70B | -12,1x |
| Champions Oncology, Inc. | CSBR | ██% | $82M | 32,9x |
| Cel Sci Corp | CVM | ██% | $29M | -0,9x |
| Dbv Technologies S.A. | DBVT | ██% | $1.24B | -3,3x |
| Dbv Technologies S.A. | DBVTF | ██% | $10K | -x |
| Ginkgo Bioworks Holdings, … | DNA | ██% | $395M | -13,9x |
| Denali Therapeutics Inc. | DNLI | ██% | $3.23B | -8,7x |
| Precision Biosciences Inc | DTIL | ██% | $137M | -2,2x |
| Dyadic International Inc | DYAI | ██% | $31M | -7,3x |
| Editas Medicine, Inc. | EDIT | ██% | $255M | -0,8x |
| Eloxx Pharmaceuticals, Inc. | ELOX | ██% | $710K | -x |
| Elutia Inc. | ELUT | ██% | $45M | 0,9x |
| Engene Holdings Inc. | ENGN | ██% | $453M | 3,7x |
| Entera Bio Ltd. | ENTX | ██% | $53M | 8,5x |
| Viskase Holdings, Inc. | ENZN | ██% | $4M | -x |
| Estrella Immunopharma, Inc. | ESLA | ██% | $45M | -3,1x |
| Evaxion A/S | EVAX | ██% | $33M | -x |
| Exelixis, Inc. | EXEL | ██% | $11.56B | 14,8x |
| Exozymes Inc. | EXOZ | ██% | $71M | -x |
| Fate Therapeutics Inc | FATE | ██% | $143M | -1,3x |
| 4d Molecular Therapeutics, … | FDMT | ██% | $504M | -3,0x |
| Fennec Pharmaceuticals Inc. | FENC | ██% | $219M | 1758,3x |
| Finch Therapeutics Group, … | FNCH | ██% | $15M | 0,5x |
| Futuretech Ii Acquisition … | FTII | ██% | $52M | -x |
| Futuretech Ii Acquisition … | FTIIU | ██% | $14M | -x |
| Gilead Sciences, Inc. | GILD | ██% | $174.11B | 20,5x |
| Monte Rosa Therapeutics, … | GLUE | ██% | $1.37B | 59,5x |
| Genenta Science S.P.A. | GNTA | ██% | $16M | -x |
| Green Planet Bio … | GPLB | ██% | $340K | -x |
| Greenland Mines Ltd | GRML | ██% | $44M | -x |
| Halozyme Therapeutics, Inc. | HALO | ██% | $7.54B | 23,8x |
| Humacyte, Inc. | HUMA | ██% | $131M | -3,3x |
| Immunitybio, Inc. | IBRX | ██% | $7.22B | -3,6x |
| Inhibikase Therapeutics, Inc. | IKT | ██% | $238M | -1,0x |
| Imagenebio, Inc. | IMA | ██% | $56M | -x |
| Immunocore Holdings Plc | IMCR | ██% | $1.54B | -x |
| Immatics N.V. | IMTX | ██% | $1.34B | -x |
| Immunovant, Inc. | IMVT | ██% | $5.06B | -14,5x |
| In8bio, Inc. | INAB | ██% | $14M | -x |
| Inhibrx Biosciences, Inc. | INBX | ██% | $873M | -6,8x |
| Mink Therapeutics, Inc. | INKT | ██% | $45M | -1,5x |
| Inmune Bio, Inc. | INMB | ██% | $33M | -2,5x |
| Intensity Therapeutics, Inc. | INTS | ██% | $14M | -2,2x |
| Iovance Biotherapeutics, Inc. | IOVA | ██% | $1.41B | -4,5x |
| Century Therapeutics, Inc. | IPSC | ██% | $394M | -0,7x |
| Invivyd, Inc. | IVVD | ██% | $360M | -0,4x |
| Jasper Therapeutics, Inc. | JSPR | ██% | $22M | -3,2x |
| Kalaris Therapeutics, Inc. | KLRS | ██% | $136M | -x |
| Klotho Neurosciences, Inc. | KLTO | ██% | $56M | -x |
| Kodiak Sciences Inc. | KOD | ██% | $2.64B | -2,5x |
| Krystal Biotech, Inc. | KRYS | ██% | $7.56B | 36,9x |
| Kymera Therapeutics, Inc. | KYMR | ██% | $6.91B | -17,8x |
| Kyverna Therapeutics, Inc. | KYTX | ██% | $530M | -x |
| Ladrx Corp | LADX | ██% | $20K | -x |
| Lineage Cell Therapeutics, … | LCTX | ██% | $387M | -4,7x |
| Lenz Therapeutics, Inc. | LENZ | ██% | $293M | -6,7x |
| Liminatus Pharma, Inc. | LIMN | ██% | $7M | -x |
| Leonabio, Inc. | LONA | ██% | $106M | -x |
| Lexeo Therapeutics, Inc. | LXEO | ██% | $414M | -0,4x |
| Maze Therapeutics, Inc. | MAZE | ██% | $1.43B | -x |
| Mesoblast Ltd | MESO | ██% | $2.07B | -x |
| Meiragtx Holdings Plc | MGTX | ██% | $737M | -3,4x |
| Metagenomi Therapeutics, Inc. | MGX | ██% | $50M | -x |
| Molecular Partners Ag | MOLN | ██% | $162M | -x |
| Moderna, Inc. | MRNA | ██% | $19.71B | -3,2x |
| Neurocrine Biosciences Inc | NBIX | ██% | $13.27B | 27,7x |
| Nkgen Biotech, Inc. | NKGN | ██% | $2M | -0,1x |
| Neumora Therapeutics, Inc. | NMRA | ██% | $348M | -3,9x |
| Novavax Inc | NVAX | ██% | $1.30B | 3,0x |
| Ocugen, Inc. | OCGN | ██% | $559M | -4,3x |
| Outlook Therapeutics, Inc. | OTLK | ██% | $22M | -0,2x |
| Palisade Bio, Inc. | PALI | ██% | $312M | -0,2x |
| Passage Bio, Inc. | PASG | ██% | $25M | -0,6x |
| Vaxcyte, Inc. | PCVX | ██% | $7.67B | -20,4x |
| Biomx Inc. | PHGE | ██% | $22M | 1,5x |
| Pluri Inc. | PLUR | ██% | $33M | -1,4x |
| Protalix Biotherapeutics, Inc. | PLX | ██% | $176M | 41,2x |
| Pharmacyte Biotech, Inc. | PMCB | ██% | $7M | 0,3x |
| Prime Medicine, Inc. | PRME | ██% | $599M | -1,5x |
| Prokidney Corp. | PROK | ██% | $527M | -x |
| Pelthos Therapeutics Inc. | PTHS | ██% | $66M | -x |
| Qiagen N.V. | QGEN | ██% | $8.86B | -x |
| Quince Therapeutics, Inc. | QNCX | ██% | $5M | -1,7x |
| Qrons Inc. | QRON | ██% | $150K | -x |
| Replimune Group, Inc. | REPL | ██% | $606M | -3,8x |
| Repligen Corp | RGEN | ██% | $6.66B | 136,3x |
| Regenxbio Inc. | RGNX | ██% | $439M | -1,8x |
| Relay Therapeutics, Inc. | RLAY | ██% | $1.87B | -2,0x |
| Revolution Medicines, Inc. | RVMD | ██% | $19.43B | -11,1x |
| Recursion Pharmaceuticals, Inc. | RXRX | ██% | $1.62B | -4,7x |
| Sab Biotherapeutics, Inc. | SABS | ██% | $271M | 20,4x |
| Sana Biotechnology, Inc. | SANA | ██% | $846M | -2,1x |
| Scilex Holding Co | SCLX | ██% | $49M | -0,4x |
| Scinai Immunotherapeutics Ltd. | SCNI | ██% | $2M | -287,8x |
| Sangamo Therapeutics, Inc | SGMO | ██% | $91M | -1,6x |
| Solid Biosciences Inc. | SLDB | ██% | $726M | -0,9x |
| Silexion Therapeutics Corp | SLXN | ██% | $4M | -x |
| Senti Biosciences, Inc. | SNTI | ██% | $26M | -1,1x |
| Scholar Rock Holding … | SRRK | ██% | $5.35B | -18,5x |
| Surrozen, Inc./De | SRZN | ██% | $335M | -0,5x |
| Sutro Biopharma, Inc. | STRO | ██% | $392M | -1,0x |
| Protara Therapeutics, Inc. | TARA | ██% | $270M | -2,1x |
| Tarsus Pharmaceuticals, Inc. | TARS | ██% | $2.99B | -12,4x |
| Tc Biopharm (Holdings) … | TCBPY | ██% | $10K | -x |
| Tscan Therapeutics, Inc. | TCRX | ██% | $57M | -4,6x |
| Bio-Techne Corp | TECH | ██% | $8.34B | 102,8x |
| Tectonic Therapeutic, Inc. | TECX | ██% | $575M | -8,9x |
| Instil Bio, Inc. | TIL | ██% | $54M | -1,1x |
| Tenaya Therapeutics, Inc. | TNYA | ██% | $151M | -2,5x |
| Tourmaline Bio, Inc. | TRML | ██% | $1.23B | -3,5x |
| Taysha Gene Therapies, … | TSHA | ██% | $1.25B | -3,0x |
| Titan Pharmaceuticals Inc | TTNP | ██% | $6M | -0,5x |
| Tevogen Bio Holdings … | TVGN | ██% | $18M | -x |
| Twist Bioscience Corp | TWST | ██% | $3.08B | -12,6x |
| Voyager Acquisition Corp./Cayman … | VACH | ██% | $374M | 41,6x |
| Voyager Acquisition Corp./Cayman … | VACHU | ██% | $68M | 6,7x |
| Valneva Se | VALN | ██% | $530M | -x |
| Vericel Corp | VCEL | ██% | $1.59B | 96,5x |
| Vir Biotechnology, Inc. | VIR | ██% | $1.47B | -2,0x |
| Vivosim Labs, Inc. | VIVS | ██% | $4M | -x |
| Vor Biopharma Inc. | VOR | ██% | $882M | -0,6x |
| Vaxart, Inc. | VXRT | ██% | $151M | 9,3x |
| Voyager Therapeutics, Inc. | VYGR | ██% | $234M | 570,6x |
| Windtree Therapeutics Inc … | WINT | ██% | $340K | -0,4x |
| X4 Pharmaceuticals, Inc | XFOR | ██% | $402M | 6,4x |
| Zeo Scientifix, Inc. | ZEOX | ██% | $17M | -x |
| Zivo Bioscience, Inc. | ZIVO | ██% | $25M | -31,3x |
| Zura Bio Ltd | ZURA | ██% | $559M | -x |
Частые вопросы
-
Стоит ли покупать акции Kyverna Therapeutics, Inc.?
Наш ИИ анализирует Kyverna Therapeutics, Inc. ежедневно. Проверьте сигнал выше для последней рекомендации. Всегда проводите собственное исследование перед инвестированием.
-
Насколько точны прогнозы Kyverna Therapeutics, Inc.?
Наш ИИ достигает корреляции Спирмена 55% для этой акции, со средней точностью выше 67% по более чем 4 000 акциям, анализируемым ежедневно.
-
Как часто обновляются прогнозы?
Прогнозы Kyverna Therapeutics, Inc. обновляются ежедневно с использованием последних рыночных данных и ИИ-моделей.
Готовы инвестировать умнее?
Присоединяйтесь к тысячам инвесторов, использующих ИИ-прогнозы акций
Зарегистрироваться бесплатно✓ Бесплатный аккаунт · ✓ Более 4 000 акций · ✓ Ежедневные обновления
Ищете более глубокий анализ Kyverna Therapeutics, Inc.?
Посмотреть полный институциональный анализ на Intratio →ИИ-прогнозы основаны на исторических закономерностях и не должны быть единственным основанием для инвестиционных решений. Прошлые результаты не гарантируют будущих доходов. Всегда проводите собственное исследование.